THE HUB

Professor Ahmed Mudawi Musa Mohamed

Ahmed Mudawi Musa Mohamed is a professor of immunology and a physician (MRCPI) specialist in Internal Medicine, Infectious Diseases and Tropical Medicine. Professor Musa has cumulative experience in vaccines and new treatment modalities development for visceral leishmaniasis and Post kala-azar dermal leishmaniasis as an immunologist and a clinical Trialist. He joined the Institute of Endemic Diseases, university of Khartoum in 2000 and since that he has been working as an immunologist and a clinician in the endemic diseases in both tertiary and primary care setting. Professor Musa was recently (31 Jan 2019) appointed as Honorary Professor in the Hull York Medical School (HYMS) in the United Kingdom. He is now giving specialist consultations in the diagnosis and management of various infectious diseases in Sudan. He promoted many MSc and Ph D students in immunology of infectious diseases mainly leishmaniasis and tuberculosis, virology and schistosomiasis. He was qualified in the University of Khartoum, university of London, the Royal College of Physicians in London and Ireland. He was the director of the institute of Endemic Diseases, University of Khartoum since Jan 2011 to December 2019 and the head of the department of clinical pathology & Immunology. Professor Musa is a regular speaker in local, regional and international medical and scientific conferences. His published work changed the guidelines of treatment of leishmaniasis. He published almost 100 publications in reputable journals (Researchgate.net, Ahmed Mudawi Musa) mainly on immunology, infectious and tropical diseases.

Dr. Sahar M. Bakhiet

Dr. Sahar M. Bakhiet is currently the head department of Molecular biology at the Institute of Endemic diseases and research coordinator at the Mycetoma Research Centre – University of Khartoum. Her research activities have included the immunology and molecular biology of different neglected diseases with special emphasis on Mycetoma and Leishmaniasis. She has published widely in this area and her publications range from epidemiology and basic science through to community engagement projects. She is supervising M.Sc ad Ph.D. students in this field and participates in different training programs.

Additionally, she is participating in the first-ever clinical trial in Mycetoma funded by DNDi and is responsible for all the laboratory management. Dr Sahar also is working as on major grant funding for two significant programmes of global health research funded by NIHR UK. Moreover, she is an active member of the Global Mycetoma Working Group.

In addition to her scientific work, Dr. Sahar has extensive reach within the public community through her public engagement activities to which she is highly committed.

Prof. Alexandro Bonifaz

a_bonifaz@yahoo.com.mx

Prof Bonifaz got great interest in mycetoma as it is a common condition in Mexico, and it has many impacts on patients in affected endemic regions. In Mexico it is commonly actinomycetoma caused Nocardia and Actinomadure species. He worked extensively on actinomycetes, especially on Nocardia brasiliensis and other species. Also, he studied the actinomycetoma epidemiology, diagnosis and he reported on new treatments with first-line antibiotics. He reported on the largest epidemiological study on mycetoma in Mexico,

He currently developing in vitro susceptibility test for Nocardia strains, isolated from mycetoma and nocardiosis. With regard to eumycetoma, he had worked together with Dr. van de Sande of Erasmus medical centre on the most accurate identification test for cryptic strains of mycetoma agents in Mexico, some of them are different from those reported in Africa.